Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



 Company News
Orexigen Therapeutics, Inc. (OREX) Announces Allowance Of New U.S. Patent For Contrave (Naltrexone Hcl / Bupropion Hcl Extended Release) 11/21/2014 10:13:32 AM
Orexigen Therapeutics, Inc. (OREX) Reports Results For The Third Quarter Ended September 30, 2014 11/10/2014 8:46:48 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The Credit Suisse Healthcare Conference 11/7/2014 8:22:33 AM
Orexigen Therapeutics, Inc. (OREX) To Host Third Quarter 2014 Financial Results Conference Call And Webcast 11/5/2014 7:51:18 AM
Orexigen Therapeutics, Inc. (OREX) Announces Contrave® (naltrexone HCI And Bupropion HCI Extended Release) Data Presentations At The ObesityWeek Meeting In Boston 10/31/2014 7:32:20 AM
Takeda Pharmaceuticals And Orexigen Therapeutics, Inc. (OREX) Announce Availability Of CONTRAVE® (naltrexone HCI And bupropion HCI) Extended-Release Tablets For Chronic Weight Management In Obese Adults 10/20/2014 8:22:26 AM
Orexigen Therapeutics, Inc. (OREX) Pockets $100 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd. (TKPYY) 10/15/2014 7:00:15 AM
Orexigen Therapeutics, Inc. (OREX) To Present At The Bank of America (BAC) Merrill Lynch Global Healthcare Conference 9/17/2014 8:06:03 AM
Orexigen Therapeutics, Inc. (OREX) To Host Conference Call And Webcast At 8:30 AM Eastern Time September 11, 2014 9/11/2014 8:14:22 AM
FDA Approves Orexigen Therapeutics, Inc. (OREX)'s Long-Awaited Weight Loss Drug Contrave 9/11/2014 5:59:03 AM